New pill CT7439 enters human testing for Hard-to-Treat cancers

NCT ID NCT06600789

Recruiting now Disease control Sponsor: Carrick Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called CT7439, taken as a capsule, in about 50 people with solid tumors that have spread or cannot be removed. The study will first test CT7439 alone, then in combination with other cancer treatments. The main goals are to check safety, find the best dose, and see how the body handles the drug. It is too early to know if CT7439 will shrink tumors or improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CT7439 (an experimental cancer drug taken as a capsule by mouth)
What this could lead to: If it works, this could point toward a new treatment option for people with solid tumors that have not responded to other therapies.
What could go wrong: This is a very early, small trial (50 people) focused mainly on safety and dosing. It is too soon to know if CT7439 will be effective or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID MALIGNANCIES

Contacts and locations

Locations

Research site 01
RECRUITING

San Antonio, Texas, 78229, United States
Research site 02
RECRUITING

Fairfax, Virginia, 22031, United States
Research site 03
RECRUITING

Dallas, Texas, 75230-2571, United States
Research site 04
RECRUITING

Oxford, OX37LE, United Kingdom
Research site 05
RECRUITING

Manchester, M20 4GJ, United Kingdom
Research site 06
RECRUITING

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.